Interview with Sixty Degrees Pharma (Nasdaq: SXTP) CEO Geoff Dow

Learn about Sixty Degrees Pharma (Nasdaq: SXTP) from CEO Geoff Dow. In this exclusive interview with Dow, gain insight into the company's mission to develop and commercialize new therapies for a range of infectious diseases, including its FDA-approved malaria preventative treatment ARAKODA® and the Company's current pipeline development programs for Tafenoquine and Celgosivir targeting COVID-19, fungal, tick-borne, and other viral diseases. Learn more about this game-changing small-cap stock by visiting SXTPinfo.com today. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. Sixty Degrees is a client of RedChip Companies, Inc. Sixty Degrees agreed to pay RedChip Companies, Inc. a $9,500 monthly cash fee, beginning in March 2023, and $40,000 of Rule 144 stock (based on the 30-day average price after the IPO) for six months of investor awareness services. For full disclosure, visit RedChip.com/disclosures.